Starpharma Holdings PE Ratio 2011-2021 | SPHRY
Current and historical p/e ratio for Starpharma Holdings (SPHRY) from 2011 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Starpharma Holdings PE ratio as of May 25, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Starpharma Holdings PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.216B |
$0.002B |
|
Starpharma Holdings Limited is engaged in the development of dendrimer products for pharmaceutical, life science and other applications. The Company's primary product in development is VivaGel, a microbicide gel for women used for the prevention and treatment of bacterial vaginosis and a range of sexually transmitted diseases. It also develops dendrimers as specialty chemicals for industrial applications. Starpharma Holdings Limited is headquartered in Melbourne, Australia.
|
